Clinical Trial Update: A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bendamustine in indolent non-Hodgkin's lymphoma refractory to rituximab; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Indolent B-cell NHL | Phase 3 | Status: TERMINATED